Conflict of interest declaration: Richard W Orrell

This submission is more than 12 months old!

Updated on: 15 August 2017

Roles in: Neuromuscular Group

1. In the past 36 months have you accepted the following from a commercial organisation with a financial interest in the broad topic area of the CRG?

a) Support for attending meetings, including sabbaticals and study tours (this covers travel, accommodation and/or hospitality)?
No

b) Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events?
No

c) Fees for organising education?
No

d) Grants and contracts?
Yes - Alnylam Pharmaceuticals: APOLLO: a phase 3 multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Patisiran (ALN-TTR02) in transthyretin (TTR)-mediated polyneuropathy (familial amyloidotic polyneuropathy-FAP). Coinvestigator. 2015- ISIS Pharmaceuticals: A phase 3 open-label extension study to assess the long-term safety and efficacy of ISIS 420915 in patients with familial amyloid polyneuropathy (FAP). Coinvestigator. 2015-

e) Funds for a member of staff?
No

f) Fees for consulting?
Yes - Chair of Data and Safety Monitoring Committee. Effects of ODM-109 on Respiratory Function in patients with ALS. Orion Pharmaceuticals. (2015- 2017)

g) Royalty or licences payments?
No

2. In the past 36 months have you, your spouse/partner or an immediate family member been employed by or do you or they own a commercial organization with a financial interest in the broad topic area of the CRG?
No

3. Do you own stocks or shares in a commercial organization with a financial interest in the broad topic area of the CRG?
No

4. Do you hold any patents (planned, issued or pending) for products relevant to the broad topic area of the CRG?
No

5. Do you have any other competing interests (financial or non-financial)?
No